Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy

Dale S. Adler, Hillard Lazarus, Ravi Nair, Jonathan L. Goldberg, Nicholas J. Greco, Tom Lassar, Mary J. Laughlin, Hiranmoy Das, Vincent J. Pompili

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.

Original languageEnglish (US)
Pages (from-to)506-514
Number of pages9
JournalFrontiers in Bioscience - Elite
Volume3 E
Issue number2
StatePublished - Jan 1 2011

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Bone
Blood
Stem Cells
Bone Marrow
Safety
Enzymes
Myocardium
Ischemia
Nervous System
Cardiac Arrhythmias
Myocardial Infarction
Therapeutics

Keywords

  • Autologous
  • Bone marrow
  • CD133
  • Chronic
  • Efficacy
  • Ischemi
  • Myocardial
  • Safety
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Adler, D. S., Lazarus, H., Nair, R., Goldberg, J. L., Greco, N. J., Lassar, T., ... Pompili, V. J. (2011). Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. Frontiers in Bioscience - Elite, 3 E(2), 506-514.

Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. / Adler, Dale S.; Lazarus, Hillard; Nair, Ravi; Goldberg, Jonathan L.; Greco, Nicholas J.; Lassar, Tom; Laughlin, Mary J.; Das, Hiranmoy; Pompili, Vincent J.

In: Frontiers in Bioscience - Elite, Vol. 3 E, No. 2, 01.01.2011, p. 506-514.

Research output: Contribution to journalArticle

Adler, DS, Lazarus, H, Nair, R, Goldberg, JL, Greco, NJ, Lassar, T, Laughlin, MJ, Das, H & Pompili, VJ 2011, 'Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy', Frontiers in Bioscience - Elite, vol. 3 E, no. 2, pp. 506-514.
Adler DS, Lazarus H, Nair R, Goldberg JL, Greco NJ, Lassar T et al. Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. Frontiers in Bioscience - Elite. 2011 Jan 1;3 E(2):506-514.
Adler, Dale S. ; Lazarus, Hillard ; Nair, Ravi ; Goldberg, Jonathan L. ; Greco, Nicholas J. ; Lassar, Tom ; Laughlin, Mary J. ; Das, Hiranmoy ; Pompili, Vincent J. / Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. In: Frontiers in Bioscience - Elite. 2011 ; Vol. 3 E, No. 2. pp. 506-514.
@article{ffa33303dbb44a98b1b178144975bf97,
title = "Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy",
abstract = "The Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.",
keywords = "Autologous, Bone marrow, CD133, Chronic, Efficacy, Ischemi, Myocardial, Safety, Therapy",
author = "Adler, {Dale S.} and Hillard Lazarus and Ravi Nair and Goldberg, {Jonathan L.} and Greco, {Nicholas J.} and Tom Lassar and Laughlin, {Mary J.} and Hiranmoy Das and Pompili, {Vincent J.}",
year = "2011",
month = "1",
day = "1",
language = "English (US)",
volume = "3 E",
pages = "506--514",
journal = "Frontiers in Bioscience - Elite",
issn = "1945-0494",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy

AU - Adler, Dale S.

AU - Lazarus, Hillard

AU - Nair, Ravi

AU - Goldberg, Jonathan L.

AU - Greco, Nicholas J.

AU - Lassar, Tom

AU - Laughlin, Mary J.

AU - Das, Hiranmoy

AU - Pompili, Vincent J.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.

AB - The Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.

KW - Autologous

KW - Bone marrow

KW - CD133

KW - Chronic

KW - Efficacy

KW - Ischemi

KW - Myocardial

KW - Safety

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79957809802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957809802&partnerID=8YFLogxK

M3 - Article

C2 - 21196330

AN - SCOPUS:79957809802

VL - 3 E

SP - 506

EP - 514

JO - Frontiers in Bioscience - Elite

JF - Frontiers in Bioscience - Elite

SN - 1945-0494

IS - 2

ER -